1-Methyl-2-benzyl-4-oxo-piperidin | 21823-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Methyl-2-benzyl-4-oxo-piperidin
• 英文别名: (1)-2-benzyl-1-methylpiperidin-4-one；2-benzyl-1-methylpiperidin-4-one；(+/-)-2-benzyl-1-methylpiperidine-4-one；1-Methyl-2-(phenylmethyl)-4-piperidinone
• CAS: 21823-56-3
• 化学式: C₁₃H₁₇NO
• 分子量: 203.284
• InChiKey: DOIPFNDHIMPNJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-bromo-2-(4-fluorophenyl)-3-(pyridin-4-yl)-1-triisopropylsilyl-1H-pyrrole 、 1-Methyl-2-benzyl-4-oxo-piperidin 在 叔丁基锂 作用下， 生成
  参考文献：
  名称：

  Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses

  摘要：

  化合物的结构式（I）：[其中：A为吡咯环；R1为可选取代的苯或萘基团；R2为可选取代的吡啶或嘧啶基团；R3代表具有下述结构的基团-X-R4，其中X为单键或烯基链，R4为可选取代的含氮杂环基团；所选取自8-氮杂双环[3.2.1]辛烯基、9-氮杂双环[3.3.1]壬烯基和喹啉环基团，前提是所述取代基R1和R3连接到所述吡咯环的两个相邻原子，这两个原子与所述取代基R2连接的吡咯环原子相邻]具有出色的抑制炎症细胞因子产生活性。

  公开号：

  EP1243589A1

文献信息

• Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040054173A1

  公开（公告）日：2004-03-18

  Compounds having activity against production of an inflammatory cytokine of formula (I)′: 1 A′ is pyrrole; R 1′ is phenyl or naphthyl; R 2′ is pyridyl or pyrimidinyl; R 3′ is (IIa)′, (IIb)′ or (IIc)′: 2 m′ is 1; E′ is nitrogen; D′ is >C(R 5′ )—, R 5′ is hydrogen, Substituent &agr;′ or Substituent &bgr;′; B′ is nitrogen-containing 5-membered heterocyclic; R 4′ is 1 to 3 substituents from Substituent &agr;′, Substituent &bgr;′ and Substituent &ggr;′; R 1′ and R 3′ are bonded to two atoms of the pyrrole adjacent to the pyrrole atom bonded to R 2′ ; Substituent &agr;′ is hydroxyl, nitro, cyano, halogen, alkoxy, halogeno alkoxy, alkylthio, halogeno alkylthio or —NR a′ R b′ ; R a′ and R b′ are hydrogen, alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl, or R a′ and R b′ with the nitrogen atom form a heterocyclyl; Substituent &bgr;′ is alkyl, alkenyl, alkynyl, aralkyl or cycloalkyl; Substituent &ggr;′ is oxo, hydroxyimino, alkoxyimino, alkylene, alkylenedioxy, alkylsulfinyl, alkylsulfonyl, aryl, aryloxy, alkylidenyl or aralkylidenyl.

  具有对抗公式(I)′炎症细胞因子生成活性的化合物： 1 A′是吡咯；R 1′ 是苯基或萘基；R 2′ 是吡啶基或嘧啶基；R 3′ 是(IIa)′，(IIb)′或(IIc)′： 2 m′是1；E′是氮；D′是>C(R 5′ )—, R 5′ 是氢，取代基α′或取代基β′；B′是含氮的5-成员杂环；R 4′ 是来自取代基α′，取代基β′和取代基γ′的1至3个取代基；R 1′ 和R 3′ 分别与吡咯环上与R 2′ 相连的吡咯原子的两个相邻原子成键；取代基α′是羟基，硝基，氰基，卤素，烷氧基，卤代烷氧基，烷基亚砜，卤代烷基亚砜或—NR a′ R b′ ；R a′ 和R b′ 是氢，烷基，烯基，炔基，芳烷基或烷基亚磺酰基，或者R a′ 和R b′ 与氮原子形成杂环；取代基β′是烷基，烯基，炔基，芳烷基或环烷基；取代基γ′是氧代，羟基亚胺，烷氧基亚胺，亚烷基，亚烷基二氧，烷基亚磺酰基，烷基亚磺酰基，芳基，芳氧基，亚烷基或芳亚烷基。
• Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: Part 2
  作者：Akira Nakao、Nobuyuki Ohkawa、Takayoshi Nagasaki、Takashi Kagari、Hiromi Doi、Takaichi Shimozato、Shigeru Ushiyama、Kazumasa Aoki

  DOI：10.1016/j.bmcl.2010.03.022

  日期：2010.4

  previously reported a novel pyrrole derivative 1 which possesses a tetrahydropyridine group at the β-position with a proinflammatory cytokine TNFα production inhibitor. Herein, we report the synthesis and biological activity of N- and α-position substituted tetrahydropyridine derivatives. In this series, we found that compound 3o showed good inhibitory activity in vitro (inhibition of lipopolysaccharide

  我们以前曾报道过一种新颖的吡咯衍生物1，它在β位置具有四氢吡啶基团，并带有促炎性细胞因子TNFα产生抑制剂。在此，我们报道了N-位和α-位取代的四氢吡啶衍生物的合成和生物活性。在本系列中，我们发现化合物3o在体外显示出良好的抑制活性（抑制脂多糖（LPS）诱导的人全血中TNFα的产生，IC 50  = 0.44μM），化合物3i在体内表现出有效的抑制活性（抑制LPS诱导的小鼠TNFα产生，ID 50  = 1.42 mg / kg）。
• COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY
  申请人：Sankyo Company, Limited

  公开号：EP1352906A1

  公开（公告）日：2003-10-15

  [Object] The object of the present invention is to provide a composition for the prophylaxis or treatment of hepatopathy. [Solution] A composition containing as an active ingredient a compound of formula (I), or a pharmacologically acceptable salt, ester or other derivative thereof for the prophylaxis or treatment of hepatopathy: [wherein: A is a pyrrole ring; R1 is an optionally substituted aryl or heteroaryl group; R2 is an optionally substituted heteroaryl group; R3 represents a group of the formula -X-R4, wherein X is a single bond or an optionally substituted alkylene, alkenylene or alkynylene group, and R4 is a substituted cycloalkyl group, a substituted aryl group, an optionally substituted heterocyclyl group, an optionally substituted heteroaryl group, or -NRaRb, wherein each of Ra and Rb is a hydrogen atom or an alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl group; PROVIDED THAT said substituents R1 and R3 are bonded to the two atoms of said pyrrole ring which are adjacent to the atom of the pyrrole ring to which said substituent R2 is bonded].

  目的 本发明的目的是提供一种用于预防或治疗肝病的组合物。 [解决方案］ 一种含有式(I)化合物或其药理学上可接受的盐、酯或其他衍生物作为活性成分的组合物，用于预防或治疗肝病： 其中A 是吡咯环； R1 是任选取代的芳基或杂芳基； R2 是任选取代的杂芳基；R3代表式-X-R4的基团，其中X是单键或任选取代的亚烷基、亚烯基或亚炔基，R4是取代的环烷基、取代的芳基、任选取代的杂环烷基、任选取代的杂芳基，或-NRaRb，其中Ra和Rb各自是氢原子或烷基、烯基、炔基、芳基或烷基磺酰基；前提是所述取代基 R1 和 R3 与所述吡咯环的两个原子键合，这两个原子与所述取代基 R2 键合的吡咯环原子相邻]。
• US7122666B2
  申请人：——

  公开号：US7122666B2

  公开（公告）日：2006-10-17